These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34269949)

  • 1. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
    Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
    Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
    J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
    Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
    Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
    Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
    Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
    Low SK; Anjum Z; Mahmoud A; Joshi U; Kouides P
    Thromb Res; 2022 Nov; 219():14-21. PubMed ID: 36088710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
    Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
    World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
    Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
    J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
    Stockhammer F; Misch M; Helms HJ; Lengler U; Prall F; von Deimling A; Hartmann C
    Seizure; 2012 Apr; 21(3):194-7. PubMed ID: 22217666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
    Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Assessment of
    Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.
    Wang Y; Xing H; Guo X; Chen W; Wang Y; Liang T; Wang H; Li Y; Jin S; Shi Y; Liu D; Yang T; Xia Y; Li J; Wu J; Liu Q; Qu T; Guo S; Li H; Zhang K; Wang Y; Ma W
    Cancer Med; 2024 Jul; 13(13):e7369. PubMed ID: 38970209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
    Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
    J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
    Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
    J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.